Lindsey Shapiro, PhD, science writer —

Lindsey earned her PhD in neuroscience from Emory University in Atlanta, where she studied novel therapeutic strategies for treatment-resistant forms of epilepsy. She was awarded a fellowship from the American Epilepsy Society in 2019 for this research. Lindsey also previously worked as a postdoctoral researcher, studying the role of inflammation in epilepsy and Alzheimer’s disease.

Articles by Lindsey Shapiro

NMOSD Diagnosis Without AQP4 Antibodies Requires More Scrutiny

Reaching a neuromyelitis optica spectrum disorder (NMOSD) diagnosis in the absence of disease-causing antibodies requires careful attention from physicians in order to ensure timely treatment. That suggestion comes from a case report of a man in Nepal who had symptoms of the autoimmune disease but lacked the antibodies against…

BTK Signaling Molecules Show Altered Levels in NMOSD Patients

Key players in B-cell signaling pathways and related inflammatory molecules were elevated in the blood of people with neuromyelitis optica spectrum disorder (NMOSD) compared with healthy people, a study found. The findings suggest that targeting this signaling pathway could show therapeutic promise in NMOSD, the researchers noted. The study,…

Study: Rituximab Better Than MMF, Azathioprine in Preventing Relapses

Rituximab worked better than other treatments at preventing relapses in people with neuromyelitis optica spectrum disorder (NMOSD) who have antibodies against aquaporin-4 (AQP-4), according to a recent Chinese report. As a first-line therapy for the autoimmune disease, Rituximab outperformed both azathioprine and mycophenolate mofetil (MMF) in relapse prevention, the…